Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Accepting from the best donor; analysis of long-lifetime donor fluorescent protein pairings to optimise dynamic FLIM-based FRET experiments.

Martin KJ, McGhee EJ, Schwarz JP, Drysdale M, Brachmann SM, Stucke V, Sansom OJ, Anderson KI.

PLoS One. 2018 Jan 2;13(1):e0183585. doi: 10.1371/journal.pone.0183585. eCollection 2018.

2.

Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening.

McDonald ER 3rd, de Weck A, Schlabach MR, Billy E, Mavrakis KJ, Hoffman GR, Belur D, Castelletti D, Frias E, Gampa K, Golji J, Kao I, Li L, Megel P, Perkins TA, Ramadan N, Ruddy DA, Silver SJ, Sovath S, Stump M, Weber O, Widmer R, Yu J, Yu K, Yue Y, Abramowski D, Ackley E, Barrett R, Berger J, Bernard JL, Billig R, Brachmann SM, Buxton F, Caothien R, Caushi JX, Chung FS, Cortés-Cros M, deBeaumont RS, Delaunay C, Desplat A, Duong W, Dwoske DA, Eldridge RS, Farsidjani A, Feng F, Feng J, Flemming D, Forrester W, Galli GG, Gao Z, Gauter F, Gibaja V, Haas K, Hattenberger M, Hood T, Hurov KE, Jagani Z, Jenal M, Johnson JA, Jones MD, Kapoor A, Korn J, Liu J, Liu Q, Liu S, Liu Y, Loo AT, Macchi KJ, Martin T, McAllister G, Meyer A, Mollé S, Pagliarini RA, Phadke T, Repko B, Schouwey T, Shanahan F, Shen Q, Stamm C, Stephan C, Stucke VM, Tiedt R, Varadarajan M, Venkatesan K, Vitari AC, Wallroth M, Weiler J, Zhang J, Mickanin C, Myer VE, Porter JA, Lai A, Bitter H, Lees E, Keen N, Kauffmann A, Stegmeier F, Hofmann F, Schmelzle T, Sellers WR.

Cell. 2017 Jul 27;170(3):577-592.e10. doi: 10.1016/j.cell.2017.07.005.

PMID:
28753431
3.

Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.

Herkert B, Kauffmann A, Mollé S, Schnell C, Ferrat T, Voshol H, Juengert J, Erasimus H, Marszalek G, Kazic-Legueux M, Billy E, Ruddy D, Stump M, Guthy D, Ristov M, Calkins K, Maira SM, Sellers WR, Hofmann F, Hall MN, Brachmann SM.

Cancer Res. 2016 Jan 15;76(2):390-402. doi: 10.1158/0008-5472.CAN-14-3358. Epub 2015 Nov 17.

4.

Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.

Fritsch C, Huang A, Chatenay-Rivauday C, Schnell C, Reddy A, Liu M, Kauffmann A, Guthy D, Erdmann D, De Pover A, Furet P, Gao H, Ferretti S, Wang Y, Trappe J, Brachmann SM, Maira SM, Wilson C, Boehm M, Garcia-Echeverria C, Chene P, Wiesmann M, Cozens R, Lehar J, Schlegel R, Caravatti G, Hofmann F, Sellers WR.

Mol Cancer Ther. 2014 May;13(5):1117-29. doi: 10.1158/1535-7163.MCT-13-0865. Epub 2014 Mar 7.

5.

[Integrating the e-learning programme EGONE into the block of training in obstetrics and gynaecology].

Weninger L, Liebhardt H, Brachmann S, Varga D, Atassi Z, Wöckel A, Fegert J, Haller U, Kreienberg R.

Z Evid Fortbild Qual Gesundhwes. 2012;106(9):663-9. doi: 10.1016/j.zefq.2012.06.026. Epub 2012 Jul 6. German.

PMID:
23200210
6.

Identification of elongation factor G as the conserved cellular target of argyrin B.

Nyfeler B, Hoepfner D, Palestrant D, Kirby CA, Whitehead L, Yu R, Deng G, Caughlan RE, Woods AL, Jones AK, Barnes SW, Walker JR, Gaulis S, Hauy E, Brachmann SM, Krastel P, Studer C, Riedl R, Estoppey D, Aust T, Movva NR, Wang Z, Salcius M, Michaud GA, McAllister G, Murphy LO, Tallarico JA, Wilson CJ, Dean CR.

PLoS One. 2012;7(9):e42657. doi: 10.1371/journal.pone.0042657. Epub 2012 Sep 10.

7.

K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo.

Hofmann I, Weiss A, Elain G, Schwaederle M, Sterker D, Romanet V, Schmelzle T, Lai A, Brachmann SM, Bentires-Alj M, Roberts TM, Sellers WR, Hofmann F, Maira SM.

PLoS One. 2012;7(8):e44146. doi: 10.1371/journal.pone.0044146. Epub 2012 Aug 31.

8.

Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations.

Brachmann SM, Kleylein-Sohn J, Gaulis S, Kauffmann A, Blommers MJ, Kazic-Legueux M, Laborde L, Hattenberger M, Stauffer F, Vaxelaire J, Romanet V, Henry C, Murakami M, Guthy DA, Sterker D, Bergling S, Wilson C, Brümmendorf T, Fritsch C, Garcia-Echeverria C, Sellers WR, Hofmann F, Maira SM.

Mol Cancer Ther. 2012 Aug;11(8):1747-57. doi: 10.1158/1535-7163.MCT-11-1021. Epub 2012 May 31.

9.

Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor.

Maira SM, Pecchi S, Huang A, Burger M, Knapp M, Sterker D, Schnell C, Guthy D, Nagel T, Wiesmann M, Brachmann S, Fritsch C, Dorsch M, Chène P, Shoemaker K, De Pover A, Menezes D, Martiny-Baron G, Fabbro D, Wilson CJ, Schlegel R, Hofmann F, García-Echeverría C, Sellers WR, Voliva CF.

Mol Cancer Ther. 2012 Feb;11(2):317-28. doi: 10.1158/1535-7163.MCT-11-0474. Epub 2011 Dec 21.

10.

Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells.

Brachmann SM, Hofmann I, Schnell C, Fritsch C, Wee S, Lane H, Wang S, Garcia-Echeverria C, Maira SM.

Proc Natl Acad Sci U S A. 2009 Dec 29;106(52):22299-304. doi: 10.1073/pnas.0905152106. Epub 2009 Dec 10.

11.

p85 Associates with unphosphorylated PTEN and the PTEN-associated complex.

Rabinovsky R, Pochanard P, McNear C, Brachmann SM, Duke-Cohan JS, Garraway LA, Sellers WR.

Mol Cell Biol. 2009 Oct;29(19):5377-88. doi: 10.1128/MCB.01649-08. Epub 2009 Jul 27.

12.

A shortcut from plasma to chromatographic analysis: straightforward and fast sample preparation for analysis of green tea catechins in human plasma.

Zimmermann BF, Papagiannopoulos M, Brachmann S, Lorenz M, Stangl V, Galensa R.

J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Mar 15;877(8-9):823-6. doi: 10.1016/j.jchromb.2009.01.013. Epub 2009 Jan 21.

PMID:
19217834
13.

PI3K and mTOR inhibitors: a new generation of targeted anticancer agents.

Brachmann S, Fritsch C, Maira SM, García-Echeverría C.

Curr Opin Cell Biol. 2009 Apr;21(2):194-8. doi: 10.1016/j.ceb.2008.12.011. Epub 2009 Feb 7. Review.

PMID:
19201591
14.

Dual regulatory roles of phosphatidylinositol 3-kinase in IFN signaling.

Kaur S, Sassano A, Joseph AM, Majchrzak-Kita B, Eklund EA, Verma A, Brachmann SM, Fish EN, Platanias LC.

J Immunol. 2008 Nov 15;181(10):7316-23.

15.

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.

Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chène P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, García-Echeverría C.

Mol Cancer Ther. 2008 Jul;7(7):1851-63. doi: 10.1158/1535-7163.MCT-08-0017. Epub 2008 Jul 7.

16.

Observation of serum erythropoietin concentrations in female athletes for up to eight days after a marathon run.

Roecker L, Kowoll R, Fraszl W, Battal K, Brechtel L, Brachmann S, Meier-Buttermilch R, Gunga HC, Stangl A, Kiesewetter H.

Clin Lab. 2006;52(9-10):511-3.

PMID:
17078478
17.

Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells.

Isakoff SJ, Engelman JA, Irie HY, Luo J, Brachmann SM, Pearline RV, Cantley LC, Brugge JS.

Cancer Res. 2005 Dec 1;65(23):10992-1000.

18.

Role of phosphoinositide 3-kinase regulatory isoforms in development and actin rearrangement.

Brachmann SM, Yballe CM, Innocenti M, Deane JA, Fruman DA, Thomas SM, Cantley LC.

Mol Cell Biol. 2005 Apr;25(7):2593-606.

19.
20.

Interferon-gamma engages the p70 S6 kinase to regulate phosphorylation of the 40S S6 ribosomal protein.

Lekmine F, Sassano A, Uddin S, Smith J, Majchrzak B, Brachmann SM, Hay N, Fish EN, Platanias LC.

Exp Cell Res. 2004 Apr 15;295(1):173-82.

PMID:
15051500
21.
22.

Novel PI 3-kinase-dependent mechanisms of trypanosome invasion and vacuole maturation.

Woolsey AM, Sunwoo L, Petersen CA, Brachmann SM, Cantley LC, Burleigh BA.

J Cell Sci. 2003 Sep 1;116(Pt 17):3611-22. Epub 2003 Jul 22.

23.

Activation of the p70 S6 kinase and phosphorylation of the 4E-BP1 repressor of mRNA translation by type I interferons.

Lekmine F, Uddin S, Sassano A, Parmar S, Brachmann SM, Majchrzak B, Sonenberg N, Hay N, Fish EN, Platanias LC.

J Biol Chem. 2003 Jul 25;278(30):27772-80. Epub 2003 May 20.

24.

Phosphoinositide 3-kinase activates Rac by entering in a complex with Eps8, Abi1, and Sos-1.

Innocenti M, Frittoli E, Ponzanelli I, Falck JR, Brachmann SM, Di Fiore PP, Scita G.

J Cell Biol. 2003 Jan 6;160(1):17-23. Epub 2003 Jan 6.

25.

Inhibition of autophagy in mitotic animal cells.

Eskelinen EL, Prescott AR, Cooper J, Brachmann SM, Wang L, Tang X, Backer JM, Lucocq JM.

Traffic. 2002 Dec;3(12):878-93.

26.

Molecular balance between the regulatory and catalytic subunits of phosphoinositide 3-kinase regulates cell signaling and survival.

Ueki K, Fruman DA, Brachmann SM, Tseng YH, Cantley LC, Kahn CR.

Mol Cell Biol. 2002 Feb;22(3):965-77.

27.

Increased insulin sensitivity in mice lacking p85beta subunit of phosphoinositide 3-kinase.

Ueki K, Yballe CM, Brachmann SM, Vicent D, Watt JM, Kahn CR, Cantley LC.

Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):419-24. Epub 2001 Dec 18.

28.

Distinct roles of class I and class III phosphatidylinositol 3-kinases in phagosome formation and maturation.

Vieira OV, Botelho RJ, Rameh L, Brachmann SM, Matsuo T, Davidson HW, Schreiber A, Backer JM, Cantley LC, Grinstein S.

J Cell Biol. 2001 Oct 1;155(1):19-25.

Supplemental Content

Loading ...
Support Center